{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-025844","form_type":"8-K","ticker":"APGE","cik":"0001974640","company_name":"Apogee Therapeutics, Inc.","filed_at":"2026-06-22T11:45:06+00:00","discovered_at":"2026-06-22T11:50:00.337672+00:00","generated_at":"2026-06-22T11:50:17.819242+00:00","sec_items":["1.01","5.07","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"AbbVie to acquire Apogee Therapeutics for $135.11/share, ~$10.9B equity value","bullets":["AbbVie to acquire all outstanding shares of Apogee for $135.11 per share in cash, total equity value ~$10.9 billion.","Acquisition expected to close in Q3 2026, subject to Apogee shareholder approval and regulatory clearances.","Apogee's lead asset zumilokibart (APG777) targets IL-13 for atopic dermatitis; APG273 targets IL-13/TSLP for asthma.","Voting agreement with certain stockholders to support merger; termination fee of $381.3M payable under specified conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-025844","json":"https://secwatch.observer/filing/0001140361-26-025844.json","markdown":"https://secwatch.observer/filing/0001140361-26-025844.md","text":"https://secwatch.observer/filing/0001140361-26-025844.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126025844/0001140361-26-025844-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126025844/ef20076505_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T11:50:17.819242+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f7f52662d6b0cafc70c35497cc40dee7aaefab7e","claim":"Apogee Therapeutics, Inc. entered into Agreement and Plan of Merger with Andor LLC, Andor Merger Co., and AbbVie Inc. valued at $135.11 per Share (effective 2026-06-18).","evidence_excerpt":"On June 18, 2026, Apogee Therapeutics, Inc. (the “Company” or “Apogee”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Andor LLC, a Delaware limited liability company and a wholly owned subsidiary of Guarantor (“Parent”), Andor Merger Co., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and solely for the limited purposes set forth therein, AbbVie Inc., a Delaware corporation (“Guarantor” or “AbbVie”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126025844/0001140361-26-025844-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Andor LLC, Andor Merger Co., and AbbVie Inc."},{"label":"Value","value":"$135.11 per Share"},{"label":"Effective","value":"2026-06-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}